Promegapoietin
From Self-sufficiency
Revision as of 16:35, 28 May 2008 by DOI bot (Talk) (Citation maintenance. You can use this bot yourself! Please report any bugs.)
Promegapoietin is a drug given during chemotherapy to increase blood cell regeneration. It is a colony-stimulating factor that stimulates megakaryocyte production.[1][2]
It functions by stimulating ligands for interleukin 3 and c-Mpl.[3]
References
- ↑ Kratz-Albers K, Scheding S, Möhle R, Bühring H, Baum C, Mc Kearn J, Büchner T, Kanz L, Brugger W (2000). "Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell factor and promegapoietin". Exp Hematol. 28 (3): 335–46. doi:10.1016/S0301-472X(99)00152-6. PMID 10720698.
- ↑ Definition of promegapoietin - NCI Dictionary of Cancer Terms
- ↑ Doshi P, Giri J, Abegg A, Favara J, Huynh M, Kahn L, Minnerly J, Pegg L, Villani-Price D, Siegel N, Staten N, Thomas J, McKearn J, Smith W (2001). "Promegapoietin, a family of chimeric growth factors, supports megakaryocyte development through activation of IL-3 and c-Mpl ligand signaling pathways". Exp Hematol. 29 (10): 1177–84. doi:10.1016/S0301-472X(01)00694-4. PMID 11602319.
External links
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
